A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care
Completed
- Conditions
- Diabetes Type II
- Registration Number
- NCT01121315
- Lead Sponsor
- AstraZeneca
- Brief Summary
To describe the type II diabetes population in primary care with special reference to treatment, other diseases and mortality during the last decade. To test the hypothesis that the type or combination of per oral glucose lowering drugs have different effects on the risk of cardiovascular disease and diabetic complications.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58326
Inclusion Criteria
- Patients with type II diabetes, according to medical records, diagnosis, prescription or lab assessments
Exclusion Criteria
- Patients followed by physician for less than 6 months after diagnosis of Diabetes type II
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality The endpoints will be extracted from the medical records on one occassion, covering a period of one decade.
- Secondary Outcome Measures
Name Time Method Retinopathy, renal failure, hypoglycaemic episodes, other diabetic complications The endpoints will be extracted from the medical records on one occasion, covering a period of one decade. Time from: Metformin (MET) to Insulin (INS) versus Metformin (MET) -> Metformin (MET)+Sulfonylurea (SU) ->Insulin (INS) The endpoints will be extracted from the medical records on one occasion, covering a period of one decade. Number of consultations in primary care. Number of hospitalisations The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.
Trial Locations
- Locations (1)
Research Site
🇸🇪Uppsala, Sweden